{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:53:02Z","timestamp":1772819582483,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","ijdp.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.drugpo.2017.05.032","type":"journal-article","created":{"date-parts":[[2017,6,4]],"date-time":"2017-06-04T05:45:35Z","timestamp":1496555135000},"page":"209-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"special_numbering":"C","title":["Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting"],"prefix":"10.1016","volume":"47","author":[{"given":"Phillip","family":"Read","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Lothian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Chronister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosie","family":"Gilliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kearley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.drugpo.2017.05.032_bib0005","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.12370","article-title":"Continued low uptake of treatment for hepatitis C infection in a large community-based cohort of inner city residents","volume":"34","author":"Alavi","year":"2014","journal-title":"Liver International"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.drugpo.2017.05.032_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.drugpo.2017.05.032_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1386-6532(02)00116-6","article-title":"Epidemiology of hepatitis C virus infection in Australia","volume":"26","author":"Dore","year":"2003","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0025","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/cid\/civ197","article-title":"Hepatitis C virus therapeutic development: In pursuit of perfectovir","volume":"60","author":"Dore","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1016\/j.drugpo.2017.05.032_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0035","series-title":"67th annual meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)","article-title":"CV reinfection and injecting risk behavior following elbasvir\/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study","author":"Dore","year":"2016"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0040","series-title":"Australasian Viral Hepatitis Conference 2016","article-title":"An integrated primary health care service is effective at retaining and linking marginalised groups in hepatitis C care: A study of the Kirketon Road Centre, Kings Cross","author":"Gilliver","year":"2016"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0045","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"International Journal of Drug Policy"},{"issue":"2","key":"10.1016\/j.drugpo.2017.05.032_bib0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugpo.2011.08.005","article-title":"The accessibility, acceptability, health impact and cost implications or primary healthcare outlets that target injecting drug users: A narrative synthesis of literature","volume":"23","author":"Islam","year":"2012","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"10.1016\/j.drugpo.2017.05.032_bib0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999\u20132011","volume":"21","author":"Iversen","year":"2014","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1016\/j.drugpo.2017.05.032_bib0060","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence amongst people witha history of drug use at a community-based program in Toronto, Canada","volume":"47","author":"Mason","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"10.1016\/j.drugpo.2017.05.032_bib0070","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"Journal of Community Health"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.drugpo.2017.05.056","article-title":"The impact of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors\u2019 Health Network","volume":"47","author":"Morris","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0080","series-title":"General statement for drugs for the treatment of hepatitis C","author":"Pharmaceutical Benefits Scheme","year":"2016"},{"issue":"4","key":"10.1016\/j.drugpo.2017.05.032_bib0085","first-page":"245","article-title":"The Kirketon Road Centre\u2014Improving access to primary care for marginalised populations","volume":"41","author":"Rodgers","year":"2012","journal-title":"Australian Family Physician"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0090","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2016.119","article-title":"Direct observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-threshold drug treatment facility\u2014A new concept for treatment of patients with borderline compliance receiving opioid substitution therapy","volume":"111","author":"Schitz","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1016\/j.drugpo.2017.05.032_bib0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1353\/hpu.2012.0047","article-title":"Hepatitis C among clients of health care for the homeless primary care clinics","volume":"23","author":"Strehlow","year":"2012","journal-title":"Journal of Health Care for the Poor and Underserved"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0100","series-title":"Bloodborne viral and sexually transmitted infections in Australia: Annual Surveillance Report 2016","author":"The Kirby Institute","year":"2016"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0105","series-title":"Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016","author":"The Kirby Institute","year":"2016"},{"issue":"4","key":"10.1016\/j.drugpo.2017.05.032_bib0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s11524-012-9730-6","article-title":"Housing instability among people who inject drugs: Results from the Australian needle and syringe program survey","volume":"90","author":"Topp","year":"2012","journal-title":"Journal of Urban Health: Bulletin of the New York Academy of Medicine"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.drugpo.2006.11.005","article-title":"Case study: accessible primary health care\u2014A foundation to improve health outcomes for people who inject drugs","volume":"18","author":"van Beek","year":"2007","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0120","series-title":"International conference on primary health care","article-title":"Declaration of Alma-Ata","author":"World Health Organization","year":"1978"},{"key":"10.1016\/j.drugpo.2017.05.032_bib0125","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organization","year":"2016"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917301366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917301366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T15:51:30Z","timestamp":1569426690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395917301366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":25,"alternative-id":["S0955395917301366"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.032","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}